Big Money Hate Biotime Inc (NYSEMKT:BTX), Sentiment at 1.15

BioTime, Inc. (NYSEAMERICAN:BTX) Corporate Logo

Positions for Biotime Inc (NYSEMKT:BTX)

“Big money sentiment for Biotime Inc (NYSEMKT:BTX) in Q2 2018 decreased to 1.15, filings reveal. That’s down -0.02, from 2018Q1’s 1.17. 38 institutional investors opened new or increased holdings, while 33 sold and trimmed stakes in Biotime Inc so the sentiment has dropped. These funds own 55.26 million shares, that’s down from 56.08 million shares in 2018Q1. Funds holding Biotime Inc in top 10 was flat from 2 to 2 for the same number . 14 Investors Sold All; 19 Reduced Holdings; 26 increased stakes while 12 institutional investors bought stakes.

Largest Biotime Inc Investors

As of Q2 2018 Broadwood Capital Inc has 7.09% invested in Biotime Inc. Biotime Inc’s shareholder Dafna Capital Management Llc owns 181,600 shares as of Q2 2018. In addition, Prescott General Partners Llc reported 1.85 million shares in Biotime Inc equivalent to 0.14% of its stock exposure. The New York-based fund Raffles Associates Lp have invested about 0.08% of the fund’s stock portfolio in Biotime Inc. The New York-based fund Berson & Corrado Investment Advisors Llc holds 39,275 shares or 0.05% of their stock exposure.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies.The company has $170.13 million market cap. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis.Last it reported negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

BTX is reaching $1.34 during the last trading session, after decreased 3.60%.BioTime, Inc. has volume of 418,767 shares. Since December 8, 2017 BTX has declined 22.65% and is downtrending. BTX underperformed the S&P500 by 38.27%.

BioTime, Inc. (NYSEAMERICAN:BTX)’s quarterly earnings will be announced on March, 21., Faxor reports. Last year’s EPS was $-0.08, while now analysts expect change of 12.50 % up from current $-0.07 EPS. 0.00 % EPS growth is what analysts predict. $-0.07 EPS was announced for last quarter.

Teacher Retirement Sys Of Texas holds 0% or 17,964 shs in its capital. Douglass Winthrop Advsrs Limited Liability Com reported 10,000 shs. Dafna Cap Mngmt Limited Liability Corporation holds 0.18% or 181,600 shs. Ameritas Inv Prtnrs owns 6,005 shs or 0% of their US capital. Moors & Cabot Inc, a Massachusetts-based fund reported 46,050 shs. The New York-based Indexiq Advsrs Lc has invested 0.05% in BioTime, Inc. (NYSEAMERICAN:BTX). Blackrock holds 0% of its capital in BioTime, Inc. (NYSEAMERICAN:BTX) for 5.92 million shs. Raymond James Fin Advsr Inc has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Proshare Advisors Ltd Liability accumulated 11,797 shs. Voya Investment Mngmt Ltd Limited Liability Company has 32,496 shs. Moreover, Citadel Advsr Ltd Com has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 83,961 shs. Renaissance Techs Limited Liability Com accumulated 0% or 776,400 shs. Bank & Trust Of Montreal Can invested in 5,086 shs. State Of Wisconsin Inv Board accumulated 57,000 shs or 0% of the stock. Berson Corrado Invest Limited Liability Company invested 0.05% of its capital in BioTime, Inc. (NYSEAMERICAN:BTX).

BioTime, Inc. had 0 sales and 1 buying transaction since September 11, 2018. This’s net activity of $3,769.

For more BioTime, Inc. (NYSEAMERICAN:BTX) news brought out recently go to:,,, or The titles are as follows: “BioTime to Present New OpRegenĀ® Data at American Academy of Ophthalmology Annual Meeting on October 28th – Business Wire” brought out on October 22, 2018, “BioTime Awarded Grant From the NIH – Business Wire” on June 29, 2018, “Asterias Biotherapeutics Reports Third Quarter Results NYSE:AST – GlobeNewswire” with a publish date: November 09, 2018, “AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance – Business Wire” and the last “GlobalSCAPE Regains Compliance with NYSE American Continued Listing Standards – Business Wire” with publication date: June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.